Can First Approval Of China mRNA Vaccine Change 'COVID Zero' Approach?
Indonesia Grants Nod
Executive Summary
The first approval of a China-originated mRNA COVID-19 vaccine has come ahead of the key Communist Party Congress and Beijing's next pandemic policy decisions will be closely watched.
You may also be interested in...
Scholz Visit Paves Way For Limited China BioNTech Vaccine Use
Recent visits by foreign dignitaries and progress with local mRNA vaccines and antivirals appear to be helping some slight relaxations in China's strict COVID policies, but some experts predict it may still take months for further steps.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck and Moderna’s cancer vaccine deal; six pivotal trial readouts to look out for in Q4; Pfizer leads big pharma M&A so far this year; making the metaverse work in pharma; and a first approval for a Chinese mRNA vaccine.
Eyes On Common Prosperity, Dual Circulation Policies As China Opens Key Congress
From general economic policies around common prosperity and 'dual circulation' to its 'COVID Zero' approach, the Chinese Communist Party’s once-in-five-years National Congress will chart the country’s direction as challenges mount, growth stalls and consumption plunges.